US FDA approves 2 Teva Pharmaceutical asthma inhalers
Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns
Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders
Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up
Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps
The U.S. FDA approved two Teva Pharmaceutical Industries Ltd. asthma inhalers.
The inhalers, AirDuo RespiClick and ArmonAir RespiClick, will be available for adolescent and adult patients via prescription later this year.
